T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.81B |
| 2 |
Boeing
BA
|
+$1.68B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.33B |
| 4 |
Amphenol
APH
|
+$1.11B |
| 5 |
CME Group
CME
|
+$902M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$3.65B |
| 2 |
Advanced Micro Devices
AMD
|
+$2.51B |
| 3 |
UnitedHealth
UNH
|
+$2.06B |
| 4 |
Uber
UBER
|
+$1.84B |
| 5 |
Adobe
ADBE
|
+$1.44B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.21% |
| 2 | Healthcare | 12.77% |
| 3 | Consumer Discretionary | 11.71% |
| 4 | Financials | 11.15% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OPI
2926
DELISTED
Office Properties Income Trust
OPI
| $51K | ﹤0.01% |
51,041
+14,800
| +41% | +$22.8K |
|
2927
PMV Pharmaceuticals
PMVP
$65.6M
| $51K | ﹤0.01% |
33,600
| – | – |
|
2928
Sight Sciences
SGHT
$458M
| $51K | ﹤0.01% |
13,756
+2,485
| +22% | +$11.3K |
|
2929
Nerdy
NRDY
$94.8M
| $50K | ﹤0.01% |
30,263
+7,607
| +34% | +$9.43K |
|
2930
Atossa Therapeutics
ATOS
$24M
| $49K | ﹤0.01% |
3,413
+695
| +26% | +$13.6K |
|
2931
Holley
HLLY
$361M
| $49K | ﹤0.01% |
16,088
| – | – |
|
|
QIPT
2932
DELISTED
Quipt Home Medical
QIPT
| $49K | ﹤0.01% |
15,771
+2,942
| +23% | +$7.92K |
|
2933
Rafael Holdings
RFL
$109M
| $49K | ﹤0.01% |
29,731
| – | – |
|
|
DM
2934
DELISTED
Desktop Metal, Inc.
DM
| $49K | ﹤0.01% |
20,750
-11,479
| -36% | -$48.6K |
|
2935
Achieve Life Sciences
ACHV
$720M
| $48K | ﹤0.01% |
13,474
+2,389
| +22% | +$10.8K |
|
2936
TScan Therapeutics
TCRX
$52.8M
| $48K | ﹤0.01% |
15,479
+3,178
| +26% | +$14.4K |
|
2937
HF Foods Group
HFFG
$95.9M
| $47K | ﹤0.01% |
14,357
| – | – |
|
2938
Information Services Group
III
$244M
| $47K | ﹤0.01% |
14,041
+3,092
| +28% | +$10.3K |
|
2939
Lantronix
LTRX
$275M
| $47K | ﹤0.01% |
11,200
| – | – |
|
|
RGLS
2940
DELISTED
Regulus Therapeutics
RGLS
| $47K | ﹤0.01% |
29,597
-2,121,474
| -99% | -$3.26M |
|
2941
Ampco-Pittsburgh
AP
$191M
| $46K | ﹤0.01% |
21,600
| – | – |
|
2942
PEDEVCO
PED
$155M
| $45K | ﹤0.01% |
2,875
| – | – |
|
2943
Karyopharm Therapeutics
KPTI
$44.2M
| $44K | ﹤0.01% |
4,287
-4,693
| -52% | -$56.7K |
|
2944
Outset Medical
OM
$84.8M
| $44K | ﹤0.01% |
2,620
-2,020
| -44% | -$25.2K |
|
2945
ThredUp
TDUP
$411M
| $42K | ﹤0.01% |
29,678
+2,699
| +10% | +$3.03K |
|
|
FRGE
2946
DELISTED
Forge Global Holdings
FRGE
| $41K | ﹤0.01% |
2,902
| – | – |
|
2947
PDS Biotechnology
PDSB
$13.4M
| $41K | ﹤0.01% |
24,900
| – | – |
|
|
WGSWW
2948
DELISTED
GeneDx Holdings Warrant
WGSWW
| $41K | ﹤0.01% |
250,930
| – | – |
|
2949
X4 Pharmaceuticals
XFOR
$426M
| $41K | ﹤0.01% |
1,867
| – | – |
|
2950
Kartoon Studios
TOON
$38.7M
| $40K | ﹤0.01% |
66,240
| – | – |
|
Similar funds
T. Rowe Price Associates's Q4 2024 Portfolio in Review
As of Q4 2024, T. Rowe Price Associates held 3,110 positions worth $867B, down 0.13% from $869B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
T. Rowe Price Associates's Q4 2024 filing shows 92 new, 1,805 increased, 946 reduced and 96 closed positions. Its largest new stake was South Bow Corp: 12,337,055 shares worth $291M. The largest sale was Apple, an estimated $3.65B.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2024 buy was South Bow Corp: 12,337,055 shares worth $291M.
- T. Rowe Price Associates added most to Broadcom in Q4 2024, an estimated $2.81B increase.
- T. Rowe Price Associates's biggest Q4 2024 reduction was Apple, cutting an estimated $3.65B.
- T. Rowe Price Associates fully exited Tempus AI in Q4 2024, selling an estimated $292M.
- T. Rowe Price Associates's ten largest holdings make up 35% of its $867B portfolio in Q4 2024.
- T. Rowe Price Associates opened 92 new positions and closed 96 in Q4 2024.
- T. Rowe Price Associates's portfolio value fell 0.13% quarter-over-quarter to $867B.
Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.